Haya Taitel left the role of Director at Entera Bio Ltd., effective December 1, 2026. As of November 6, 2026, Entera Bio Ltd. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 28, 2026 to October 27, 2026, naming 1 appointment and 2 departures (Form 8-K, October 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Entera Bio Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Haya Taitel · Role: Director · Effective: 2026-12-01 · 8-K, 2026-10-27
- · In / out: In · Person: Laura Hamill · Role: Director · Effective: 2026-12-01 · 8-K, 2026-10-06
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-28
Entera Bio Ltd. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-28 to 2026-10-27. They name 3 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Entera Bio Ltd. files it.
Also on the record for Entera Bio Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G, by Venrock Healthcare Capital Partners III, L.P. | 5.1% of the class | 5%+ stakes | Source |
| August 12, 2026 | Form D, private offering | $275M sold | Form D page | Source |
| August 4, 2026 | Stake report, Schedule 13D, by BIOTECHNOLOGY VALUE FUND L P | 9.99% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G, by Longitude Capital Partners V, LLC | 4.6% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G, by Seven Fleet Capital Management LP | 4.1% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G, by TCG Crossover GP III, LLC | 7.1% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G, by Vivo Opportunity, LLC | 6.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 2.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Entera Bio Ltd. now and the warning signs.
Free to see. No signup.
Keep reading
More on Entera Bio Ltd. and the records around it.
Entera Bio Ltd. elsewhere on the record
- 5%+ stake filings Oct 2026
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Who owns it
Companies that share a holder
- Longitude Capital Partners V, LLC also filed stake reports on 3 other companies: CytomX Therapeutics, Inc. (May 2026), Mobia Medical, Inc. (May 2026), Veradermics, Incorporated (May 2026)
- Seven Fleet Horizon Master Fund LP also filed stake reports on 3 other companies: CytomX Therapeutics, Inc. (May 2026), Veradermics, Inc (May 2026), CG Oncology, Inc. (Oct 2025)
- TCG Crossover GP III, LLC also filed stake reports on 3 other companies: Research Alliance Corporation III (Aug 2026), Editas Medicine, Inc. (Jun 2026), InflaRx N.V. (May 2026)
Watch Entera Bio Ltd.
Get an email when Entera Bio Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Entera Bio Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Entera Bio Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Entera Bio Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-27 | Out | Director | 2026-12-01 | 8-K, 2026-10-27 | |
| 2026-10-06 | In | Director | 2026-12-01 | 8-K, 2026-10-06 | |
| 2026-10-06 | Out | Director | 2026-12-01 | 8-K, 2026-10-06 | |
| 2026-07-28 | Reported | not named in the filing | 8-K, 2026-07-28 |
Who leads Entera Bio Ltd., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Haya Taitel, departure reported, effective 2026-12-01 (filed 2026-10-27). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Entera Bio Ltd.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Entera Bio Ltd. (free up to 3)
Find people with the same kind of experience as the Director at Entera Bio Ltd., with the record behind each one.
Find candidates like Director at Entera Bio Ltd.Every change, in the filing's words
Departing: Haya Taitel, Director, effective 2026-12-01
On October 27, 2026, Haya Taitel notified the Board that she would step down as a director, effective December 1, 2026.
- Appointment of Dr. Juan Camilo Arjona Ferreira as Director On October 27, 2026, the Board of Directors (the "Board") of Entera Bio Ltd., a company organized under the laws of the State of Israel (the "Company"), appointed Juan Camilo Arjona Ferreira, M.D., as a Class II director of the Company, effective December 1, 2026.
- Dr. Arjona Ferreira will serve as a director until the Company's 2027 Annual Meeting of Shareholders and until his successor shall have been elected and qualified, or until his earlier death, resignation, retirement, disqualification or removal.
- Dr. Arjona Ferreira has also been appointed to serve as a member of the compensation committee of the Board, effective December 1, 2026.
- Dr. Arjona Ferreira, age 57, is a seasoned physician and pharmaceutical executive and a longtime global advocate for women's health, with more than 20 years of global clinical development experience.
- He currently serves as Head of Research & Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), leading Organon's global research and development organization, which spans early- and late-stage development, global regulatory affairs, pharmacovigilance and safety science, and medical affairs across a diverse portfolio focused on women's health.
Appointed: Laura Hamill, Director, effective 2026-12-01
On October 6, 2026, the Board of Directors (the " Board ") of Entera Bio Ltd., a company organized under the laws of the State of Israel (the " Company "), appointed Laura Hamill as a Class I director of the Company, effective December 1, 2026.
Departing: Yonatan Malca, Director, effective 2026-12-01
On October 6, 2026, Yonatan Malca notified the Board that he would step down as a director, effective December 1, 2026.
- Ms. Hamill will serve as a director until the Company's 2027 Annual Meeting of Shareholders and until her successor shall have been elected and qualified, or until her earlier death, resignation, retirement, disqualification or removal.
- Ms. Hamill has also been appointed to serve as a member of both the audit committee and corporate governance and nomination committee of the Board, in each case, effective December 1, 2026.
- Ms. Hamill, age 62, is a seasoned biopharmaceutical executive with more than 35 years of commercial leadership experience.
- She most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. Prior to Gilead, Ms. Hamill spent nearly two decades at Amgen Inc. in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations and Senior Vice President of the Intercontinental Region.
- Earlier at Amgen, she held leadership roles including Vice President of International Marketing and Business Operations in Switzerland, Vice President of U.S. Corporate Accounts and Reimbursement, and served as executive leader of Amgen's Senior Women's Advisory Council.
- Ms. Hamill currently serves on the Board of Directors of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), BB Biotech AG, and Fate Therapeutics, Inc. (Nasdaq: FATE).
Reported
Pursuant the Purchase Agreement, the Company has agreed that prior to or at such a time as a New Independent Director is appointed to the Board, as part of an orderly succession plan and otherwise in accordance with good governance practices, a current independent director will resign from the Board.
- Each of Haya Taitel and Yonatan Malca has communicated to the Board that he or she will either resign from the Board or not stand for reelection to the Board, in either case, effective upon the date that a corresponding New Independent Director is appointed or elected to the Board.
- The decision of each of Haya Taitel and Yonatan Malca to either resign or not stand for reelection did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Entera Bio Ltd.'s funding history
Tools for this story
Each opens in a new tab, filled in for Entera Bio Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.